Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05134545
Other study ID # CSP-DS1411
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 24, 2019
Est. completion date June 30, 2023

Study information

Verified date February 2023
Source Genoss Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to demonstrate the non-inferiority of GENOSS DCB versus IN.PACT Admiral DCB on late lumen loss 6 months after the procedure in patients with de novo or non-stented restenotic lesions of the superficial femoral artery and popliteal artery and to evaluate the safety. This clinical trial will be conducted on a total of 118 patients at 11 domestic institutions (taking into account the dropout rate of 30%).


Description:

In this clinical trial, IN.PACT Admiral, which is the most similar to GENOSS DCB, a test device, and the product type and purpose of use, and whose efficacy has already been proven through numerous clinical studies, was selected as a control product. Due to the nature of this clinical trial, the investigator cannot be blinded to the treatment method to which the subject is assigned, so it is designed as a double-blind design in which only the subject and the independent evaluator are blinded. For efficacy and safety evaluation, follow-up is performed up to 12 months after procedure of the clinical trial medical device. The primary endpoint of the efficay evaluation was performed by an independent evaluator and CT angiography at 6 months of in-segment late lumen loss. It is evaluated the revascularization rate, Rutherford classification, the amount of change in ABI or TBI at 1, 6, and 12 months, the procedural success rate during the clinical trial period, and the device success rate immediately after the procedure. Safety evaluation is confirmed through all adverse events, MAE (Major adverse event), vital signs, physical examination and laboratory test results that occur to the subject during the clinical trial period after procedure of the clinical trial medical device.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date June 30, 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years to 85 Years
Eligibility Inclusion Criteria: 1. = 19 years and = 85 years of age 2. Documented ischemia with Rutherford classification 2, 3, 4 or 5 3. Target lesion is in the SFA and/or PPA 4. Reference vessel diameter = 4 mm and = 7 mm by visual estimate 5. Angiographic evidence that target lesion consists of a single de novo or non-stented restenotic lesion; - 70% - 99% occluded with total lesion length = 40 mm and = 300 mm - 100% occluded with total lesion length = 100 mm - Combination lesions (a non-occlusive lesion that includes a totally occluded segment along its length) are eligible provided that (1) the combined lesion length is = 40 mm and = 300 mm and (2) the totally occluded segment is not greater than 100 mm in length. - Tandem or adjacent lesions are treated as a single lesion, the gap between the lesions is = 30 mm, and the total combined lesion length including the distance between the lesions is = 40 mm and = 300 mm Exclusion Criteria: 1. Stroke or STEMI within 3 months prior to enrollment 2. Acute thrombosis or acute aneurysm in the target lesion 3. History of or planning to have a major amputation in the leg 4. Failure to successfully cross the target lesion with a guidewire 5. Poor distal run-off artery to the ankle or lower 6. Known allergies or sensitivities to paclitaxel, shellac, vitamin E, heparin, aspirin, other anticoagulant/antiplatelet therapies or contrast agent 7. Target lesion is one of the following; - In-stent restenosis (ISR) - Restenosis after DCB procedure - Previously treated with bypass surgery - Severe concentric calcified lesions on angiography where pre-dilation cannot be performed or failed, and the procedure for the device for clinical trials is inadequate 8. Those who need stenting due to vascular dissection that restricts blood flow of Grade D or higher after pre-dilation 9. Any major (e.g., cardiac, peripheral, abdominal) intervention (including in the contralateral SFA/PPA) planned within 30 days post index procedure 10. Life expectancy, in the Investigator's opinion, is less than 12 months 11. Chronic renal insufficiency with serum creatinine > 2.5 mg/dL

Study Design


Intervention

Device:
Genoss® DCB
Peripheral Drug Coated Balloon
IN.PACT Admiral® DCB
Peripheral Drug Coated Balloon

Locations

Country Name City State
Korea, Republic of Ajou University Hospital Suwon

Sponsors (1)

Lead Sponsor Collaborator
Genoss Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary late lumen loss after procedure in patients with peripheral artery disease of femoral and popliteal artery late lumen loss between test group and control group evaluated by CT angiography in patients with peripheral artery disease of femoral and popliteal artery Follow-up CT angiography at 6 months after the procedure
Secondary Target lesion revascularization Proportion of subjects who underwent revascularization because the ABI (or TBI) decreased by 20% or more, or exceeded 0.15, or showed clinically significant ischemic symptoms compared to immediately after the procedure at 1 months, 6 months, and 12 months after procedure
Secondary Change in ABI or TBI The amount of ABI(Ankle-brachial index) or TBI(Toe-brachial index) change after the procedure compared to before the procedure is evaluated between the test group and the control group. at 1 month, 6 months, and 12 months after procedure
Secondary Changes in Rutherford classification The amount of change in Rutherford classification after the procedure compared to before the procedure is evaluated between the test group and the control group. at 1 month, 6 months, and 12 months after procedure
Secondary Restenosis rate after procedure in patients with peripheral artery disease of femoral and popliteal artery Restenosis is defined as a case where the DS(Diameter stenosis) of the reference vessel diameter is 50% or more when the successfully treated lesion is evaluated through CT angiography. Follow-up CT angiography at 6 months after procedure
Secondary Device success rate, % It is defined as a device that has successfully reached the target lesion during the procedure, undergoes normal balloon inflation and deflation, and is fully recovered without balloon rupture. immediately after the procedure
Secondary Procedural success rate, % During the clinical trial period, no postoperative death, target vessel revascularization (TVR), lower extremity amputation, or target lesion thrombosis is defined as procedural success. at 12 months after procedure
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries N/A
Completed NCT02228564 - BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A